WWB

24.2851.15%
CD

Claudia D'Augusta

Chief Financial Officer

Dr. Claudia D'Augusta Ph.D. is Chief Financial Officer of Windward Bio AG and Windward Bio Group AG from January 2025. She served as Chief Financial Officer of TiGenix NV. since May 3, 2011 and serves as its Compliance Officer. She is the Chief Financial Officer of VectivBio AG. She joined VectivBio AG in 2019. Dr. D'Augusta served as a Company Secretary of TiGenix N.V. She also served as Chief Financial Officer of Cellerix and led its merger with TiGenix. She served as Finance Director of Aquanima (Santander Group). Dr. D'Augusta has experience in the field of corporate finance, capital markets and M&A. She also served as the Chief Financial Officer of Cellerix, S.A. She was employed at BtoBfactory Ventures, S.A. During her Ph.D. She was an Assistant Professor at Bocconi, as a researcher in financial engineering at Harvard Business School and as a freelance consultant in Italy for US and Italian companies. She joined the corporate finance department of Deloitte Corporate Finance LLC in Milano, working on transactions in telecoms and Internet. She later joined Apax Partners LLP, Madrid, where she worked on M&A transactions and private placements for Internet start-ups. She served as Non-Executive Director of ReNeuron Group plc since September 06, 2017 until September 10, 2020. Dr. D'Augusta holds a Degree in Economics and a Ph.D. in Business Administration and Finance from Bocconi University in Milano. She has been an Independent Director of Bone Therapeutics SA since June 13, 2018. Prior to TiGenix, Claudia D'Augusta held various other senior financial positions across a number of international public and private companies.

Positions